Washington D.C. – In a significant development for the U.S. Food and Drug Administration (FDA), Commissioner Dr. Marty Makary has officially tendered his resignation. The departure, confirmed by multiple sources, follows a period of intense speculation and reports suggesting President Donald Trump was contemplating his removal. Makary’s tenure, which began in April 2025, was marked by several contentious decisions and a growing sense of instability within the influential regulatory body. Kyle Diamantas, currently leading the FDA’s Food division, is slated to assume the role of acting commissioner, stepping into a leadership position amidst ongoing challenges.
The circumstances surrounding Makary’s resignation point to considerable dissatisfaction within the highest echelons of government regarding his performance at the agency. The Wall Street Journal and other prominent news outlets have reported that the President’s concerns were specifically focused on Makary’s handling of key policy decisions, including the authorization of fruit-flavored e-cigarettes and the controversial approval of the abortion pill mifepristone. These issues have been flashpoints for political and public debate, placing significant pressure on the FDA and its leadership.
Makary, who served as the 27th commissioner of the FDA, held the position for just over a year. His departure adds to a pattern of leadership flux and internal unrest that has characterized the agency in recent months, raising questions about the FDA’s stability and its capacity to navigate complex regulatory landscapes.
A Rapid Succession of Departures and Controversies
The resignation of Dr. Marty Makary is not an isolated incident but rather the latest in a series of high-profile departures and internal upheavals that have plagued the FDA over the past year. This period of instability has seen seasoned regulators depart their posts, often under contentious circumstances, contributing to an environment of uncertainty within the agency.
A Year of Turbulence at the FDA:
-
April 2026: Dr. Vinay Prasad’s Second Departure: Dr. Vinay Prasad, formerly the head of the Center for Biologics Regulation and Evaluation (CBER), left the FDA for the second time in April 2026. Prasad played a crucial role in recent FDA initiatives, including the implementation of pathways for novel therapies that incorporate the concept of a "plausible mechanism" and allow for single pivotal trials for drug approval. His departure marked a significant loss of expertise in a critical area of drug development.
-
July 2025: Prasad’s Initial Resignation and Reinstatement: Prasad’s initial resignation from the FDA occurred in July 2025. This move followed considerable backlash concerning his approach to cell and gene therapy approvals, which many critics deemed overly conservative. The regulatory stance surrounding Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) gene therapy, Elevidys (delandistrogene moxeparvovec), was particularly contentious. However, in a surprising turn of events, he was reinstated as CBER head just two weeks later, reportedly at the request of the FDA, highlighting internal efforts to retain key personnel.
-
December 2025: Dr. Richard Padzur’s Brief Stint: The leadership of the Center for Drugs Regulation and Evaluation (CDER) experienced further instability with the departure of Dr. Richard Padzur in December 2025. Padzur, a seasoned oncology regulator, left his position after less than a month at the helm. He was subsequently replaced by Dr. Tracy Beth Hoeg, who became the fifth individual to lead CDER in 2025, underscoring the rapid turnover in this vital division.
-
November 2025: George Tidmarsh’s Administrative Leave: Prior to Padzur’s appointment, George Tidmarsh resigned following an administrative leave. This action was prompted by concerns raised regarding his personal conduct, further contributing to the perception of internal turmoil within the agency.
-
Peter Marks and RFK Jr. Disagreement: At CBER, the leadership transition was also marked by significant controversy. Dr. Peter Marks resigned from his position after a disagreement with Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. (RFK Jr.) over vaccine policy. Marks publicly stated that RFK Jr. was not seeking "truth and transparency" but rather "subservient confirmation of his misinformation and lies," a stark accusation that highlighted deep ideological divides within the public health landscape.
These frequent changes in leadership, particularly in critical centers like CBER and CDER, raise concerns about the continuity of regulatory policies and the agency’s ability to foster a stable and predictable environment for drug and device development.
Underlying Pressures and Criticisms
Beyond the leadership churn, the FDA has been facing a confluence of external and internal pressures that may have contributed to the current climate of unrest.
Drug Review Delays and Resource Strain: A significant challenge confronting the FDA is the persistent issue of drug review delays. These delays have been attributed by some to a series of mass layoffs within the agency, which may have impacted its capacity to process applications efficiently. The financial and staffing implications of such workforce reductions can have a direct and detrimental effect on the speed and thoroughness of regulatory reviews, potentially impacting patient access to life-saving treatments.
Accusations of Politicization: Compounding these operational challenges are accusations of politicization leveled against the FDA by former agency staffers. Such claims suggest that political considerations, rather than purely scientific and public health imperatives, may be influencing decision-making processes. If substantiated, these accusations would erode public trust in the FDA’s impartiality and its ability to act solely in the best interest of public health. The perception of political interference can undermine the agency’s credibility and its effectiveness in fulfilling its mandate.
The E-Cigarette and Mifepristone Controversies: The specific issues cited as contributing to Commissioner Makary’s departure – the authorization of fruit-flavored e-cigarettes and the handling of the abortion pill mifepristone – are particularly illustrative of the complex and politically charged environment in which the FDA operates.
-
E-cigarettes: The authorization of flavored e-cigarettes has been a deeply divisive issue. Proponents argue that these products can serve as a harm reduction tool for adult smokers seeking alternatives to traditional cigarettes. However, critics express grave concerns about the potential for these flavored products to appeal to youth, leading to increased rates of nicotine addiction among adolescents. The FDA’s regulatory approach to these products has been under intense scrutiny, with calls for stricter controls to protect public health. Makary’s handling of this matter was reportedly a key point of contention.
-
Mifepristone: The regulation of mifepristone, an essential medication for medication abortion, has become a focal point of intense legal and political battles. The FDA’s decision to approve and subsequently maintain access to mifepristone has faced significant opposition from anti-abortion groups and some political factions. Makary’s role in these decisions, and the legal challenges that have ensued, have placed the agency in a precarious position, balancing scientific evidence with deeply entrenched societal and political divisions. The pressure from the President’s office to adopt a particular stance on such a sensitive issue highlights the challenges of maintaining regulatory independence in a highly polarized environment.
Future Implications and the Path Forward
Dr. Marty Makary’s resignation and the preceding period of leadership instability at the FDA raise several critical questions about the future of the agency and its ability to effectively execute its mission.
Impact on Regulatory Certainty: The frequent changes in leadership, particularly at the commissioner level and within key centers, can create an environment of regulatory uncertainty. Pharmaceutical and biotechnology companies rely on a stable and predictable regulatory framework to guide their research, development, and investment decisions. Frequent shifts in leadership can lead to reassessments of policies and priorities, potentially delaying innovation and impacting the pipeline of new therapies.
Maintaining Scientific Independence: The accusations of politicization and the pressure from the executive branch on sensitive policy decisions underscore the ongoing challenge of safeguarding the FDA’s scientific independence. The agency’s credibility hinges on its ability to make decisions based on rigorous scientific evidence and public health considerations, free from undue political influence. The recent events will likely intensify calls for greater transparency and accountability to ensure that the FDA remains an independent arbiter of drug and device safety and efficacy.
The Role of Acting Commissioner Kyle Diamantas: The appointment of Kyle Diamantas as acting FDA commissioner presents a critical opportunity to stabilize the agency and restore confidence. Diamantas, with his experience leading the Food division, will need to demonstrate strong leadership, a commitment to scientific integrity, and the ability to navigate the complex political landscape. His immediate priorities will likely include addressing the ongoing drug review delays, fostering internal cohesion, and reassuring stakeholders that the FDA remains a robust and reliable regulatory body.
Broader Public Health Impact: The FDA plays a pivotal role in safeguarding public health by ensuring the safety and efficacy of drugs, medical devices, and food products. Any disruption or perceived weakening of the agency’s capacity can have far-reaching consequences for millions of Americans. The current period of turmoil necessitates a renewed focus on strengthening the FDA’s infrastructure, ensuring adequate resources, and reinforcing its commitment to evidence-based decision-making.
The coming months will be crucial for the FDA as it seeks to regain its footing and address the multifaceted challenges it faces. The departure of Commissioner Makary marks the end of a turbulent chapter, but the task of rebuilding stability, trust, and a clear path forward for this vital public health institution remains a significant undertaking.
About the Author
